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NeuroprotectionAlzheimer's disease (AD) is a neurodegenerative disorder characterized by synaptic loss and cognitive im-
pairments. The presence of extracellular senile plaques (mainly composed of amyloid-β (Aβ) peptide) is
an important molecular hallmark in AD and neuronal damage has been attributed, at least in part, to Aβ-
mediated toxicity. Although the molecular mechanisms involved in the pathogenesis of AD are not yet
completely understood, several lines of evidence indicate that oxidative stress and cholesterol dyshomeosta-
sis play crucial roles in mediating the synaptic loss and cognitive deﬁcits observed in AD patients. This study
evaluated the effects of Probucol, a phenolic lipid-lowering agent with anti-inﬂammatory and antioxidant
properties, on biochemical parameters related to oxidative stress and synaptic function (hippocampal gluta-
thione and synaptophysin levels; glutathione peroxidase, glutathione reductase and acetylcholinesterase ac-
tivities; lipid peroxidation), as well as on behavioral parameters related to the cognitive function (displaced
and new object recognition tasks) in Aβ-exposedmice. Animalswere treatedwith a single intracerebroventricu-
lar (i.c.v.) injection of aggregated Aβ1–40 (400 pmol/site) and, subsequently, received Probucol (10 mg/kg, i.p.)
once a day, during the following 2 weeks. At the end of treatments, Aβ1–40-exposed animals showed a signiﬁcant
impairment on learning-memory ability, which was paralleled by a signiﬁcant decrease in hippocampal synap-
tophysin levels, as well as by an increase in hippocampal acetylcholinesterase activity. Importantly, Probucol
treatment blunted the deleterious effects of Aβ1–40 on learning-memory ability and hippocampal biochemistry.
Although Aβ1–40 treatment did not change hippocampal glutathione levels and glutathione peroxidase (GPx)
and glutathione reductase (GR) activities, Aβ1–40-exposed animals showed increased hippocampal lipid peroxi-
dation and this event was completely blunted by Probucol treatment. These ﬁndings reinforce and extend the
notion of the hazardous effects of Aβ1–40 toward hippocampal synaptic homeostasis and cognitive functions.
In addition, the present results indicate that Probucol is able to counteract the cognitive and biochemical impair-
ments induced by i.c.v. Aβ1–40 administration inmice. The study is the ﬁrst to report the protective effects of Pro-
bucol (a “non-statin cholesterol-lowering drug”) against Aβ1–40-induced synaptic and behavioral impairments,
rendering this compound a promisingmolecule for further pharmacological studies on the search for therapeutic
strategies to treat or prevent AD.
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Alzheimer's disease (AD) is a neurodegenerative disorder charac-
terized by progressive cognitive deﬁcits associated with neuronal
loss, which has been reported to occur as the result of interrelated
events like oxidative stress, energetic dyshomeostasis, excitotoxicity
and neuroinﬂammation (Butterﬁeld and Lauderback, 2002; Kincses
et al., 2010; Mattson, 2004a,b). These events have been connected,
at least in part, to the extracellular deposition of amyloid β peptide
(Aβ) and protein tau hyperphosphorylation in brain areas involved
in cognitive functions (Armstrong, 2011; Braak and Braak, 1997;
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consequence relationship” between these events is not completely
understood.
Aβ toxicity is likely to be mediated by multiple different Aβ forms,
which occur as products of the activity of different proteases upon the
amyloid precursor protein (APP) (Herring et al., 2011). Aβ can misar-
range into soluble synaptotoxic oligomers (Haass and Selkoe, 2007;
Shankar et al., 2008), as well as insoluble, pre-ﬁbrillar and ﬁbrillar ag-
gregates, which ﬁnally precipitate as senile plaques (Walsh and
Selkoe, 2004). Of particular importance, in vitro studies have shown
that Aβ1–40 can liberate hydroxyl radicals upon reaction with Fe(II),
pointing to hydrogen peroxide generation as an important molecular
mechanism mediating Aβ toxicity (Tabner et al., 2002). In agreement,
in vivo studies have shown that amyloid plaques produce reactive oxy-
gen species in living, Alzheimer's models and in human Alzheimer tis-
sues (McLellan et al., 2003).
In addition to the extensively studied amyloid theory, which iden-
tiﬁes Aβ as a critical molecule involved in the pathogenesis of AD
(Hardy, 2009), accumulated evidence indicates that excessive choles-
terol in the brain also plays important roles in the development and
progression of this disorder (Longenberger and Shah, 2011). It is
noteworthy that Aβ aggregation and brain cholesterol metabolism
seem to be events that affect each other; increased cholesterol levels
play an important role in mediating Aβ aggregation and cholesterol-
lowering agents, such as HMG-CoA reductase inhibitors, may reduce
Aβ accumulation by lowering brain cholesterol levels (Longenberger
and Shah, 2011). Furthermore, clinical studies suggest that statins,
which are the most potent agents for reduction of serum cholesterol
(Gotto, 2002), via HMG-CoA reductase inhibition (Miida et al.,
2007), may reduce risk and progression of AD (Haag et al., 2009). Pos-
sible additional mechanisms associated with these effects of statins
include their “pleiotropic” effects, related to the modulation of in-
ﬂammatory, vascular and immunological events (Kalayci et al.,
2005; Pallebage-Gamarallage et al., 2010). Of particular importance,
a recent study showed that atorvastatin prevented hippocampal cell
death, neuroinﬂammation and oxidative stress induced by intracer-
ebroventricular (i.c.v.) administration of aggregated Aβ1–40 in mice
(Piermartiri et al., 2010), suggesting that statins not only prevent
Aβ aggregation (as reported by Longenberger and Shah, 2011), but
also play protective effects by decreasing the toxicity induced by ag-
gregated Aβ.
Probucol is a phenolic lipid-lowering prototype agent with anti-
inﬂammatory and antioxidant properties that has a long history of
clinical application for the treatment and prevention of cardiovascu-
lar diseases (Yamashita et al., 2008; Yamashita and Matsuzawa,
2009). Of particularly importance, a previous experimental study pro-
posed that Probucol might play beneﬁcial roles in inhibiting patho-
logical processes that could be connected to the pathogenesis of AD
(Champagne et al., 2003). That study (Champagne et al., 2003)
showed that Probucol administration to aged rats induced the syn-
thesis of hippocampal apolipoprotein E (apoE) and one of its main re-
ceptors (low density lipoprotein receptor-related protein; LRP),
substantially attenuating age-related increases in glial activation
and inducing synaptogenesis and dendritic remodeling. The results
derived from such study (Champagne et al., 2003) are important
due to the critical role of apoE in the pathogenesis of AD (Verghese
et al., 2011), as well as due to the role of LRP in mediating brain-to-
blood Aβ clearance (Zlokovic et al., 2010).
As mentioned previously, oxidative stress, neuroinﬂammation and
brain cholesterol dyshomeostasis seem to mediate the development
and progression of AD (Axelsen et al., 2011; Butterﬁeld and
Lauderback, 2002; Di Paolo and Kim, 2011; Mattson, 2004a,b). On
the other hand, Probucol, a lipid-lowering agent with anti-
inﬂammatory and antioxidant properties (Pallebage-Gamarallage et
al., 2010), has been reported to play protective effects in experimen-
tal models of neurotoxicity/neuropathology (Farina et al., 2009; Parket al., 2007), as well as attenuated age-related increases in glial acti-
vation and induced synaptogenesis and dendritic remodeling in rats
(Champagne et al., 2003). However, there are no studies on the po-
tential relationship between Probucol and Aβ-induced neurotoxicity.
Thus, we tested the hypothesis whether Probucol could inhibit the
potential detrimental effects of Aβ1–40 in the mouse hippocampal pa-
rameters and behavioral performance. We took advantage of a proto-
col previously standardized in our institute (Figueiredo et al., 2011;
Medeiros et al., 2007), which shows that a single i.c.v. Aβ1–40 injection
causes inﬂammatory responses and synaptic changes associated with
deﬁcits on learning and memory. Biochemical parameters related to
hippocampal oxidative stress and synaptic functions, aswell as behavioral
parameters related to the cognitive ability, were evaluated in an attempt
to elucidate potential events mediating damage and neuroprotection.
Material and methods
Chemicals
Probucol, β-Nicotinamide adenine dinucleotide phosphate sodium
salt reduced form, 5-5′-dithio-bis (2-nitrobenzoic) acid, glutathione
reductase from baker's yeast, reduced glutathione and dimethyl
sulfoxide were obtained from Sigma (St. Louis, MO, USA). Human
Aβ1–40 and Aβ40–1 peptides were purchased from Innovagen (Lund,
Sweden). All other chemicals were of the highest grade available
commercially.
Animals
Adult Swissmalemice (90 days old), from our own breeding colony,
were maintained at 22 °C, on a 12 h light:12 h dark cycle, with free ac-
cess to food and water. All experiments were conducted in accordance
with the Guiding Principles in theUse of Animals in Toxicology, adopted
by the Society of Toxicology (1989) and were approved by our ethics
committee for animal use at the Universidade Federal de Santa Catarina
(PP00326/CEUA 23080.013800/2009-90/UFSC).
Drug treatment protocol
Human Aβ1–40 and Aβ40–1 (reverse peptide) were prepared as
stock solutions at a concentration of 1 mg/mL in sterile 0.1 M sodium
phosphate-buffered saline (PBS) (pH 7.4), followed by aggregation by
incubation at 37 °C for 4 days. Aβ1–40 aggregation was conﬁrmed by
polyacrylamide gel electrophoresis (data not shown). The aggregated
Aβ1–40 (400 pmol/mouse), Aβ40–1 (400 pmol/mouse) or PBS (vehicle)
was administered i.c.v. as previously described (Medeiros et al., 2007;
Prediger et al., 2007). These studies, as well as the validation protocol
developed by Takeda et al. (2009), show that i.c.v. injection of Aβ1–40
causes speciﬁc dysfunction of memory processing, which correlates
well with the episodic memory deﬁcit observed in the early stages
of AD. Brieﬂy, the animals were anesthetized with isoﬂurane (1 mL/mL;
Abbot Laboratórios do Brasil Ltda., RJ, Brazil) using a vaporizer system
(SurgiVet Inc., WI, USA) and then gently restrained by hand for i.c.v. in-
jections. The sterilization of the injection site was carried out using
gauze embedded in 70% ethanol. Under light anesthesia (i.e. just that
necessary for loss of the postural reﬂex), the needlewas inserted unilater-
ally 1 mm to the right of the midline point equidistant from each eye
and 1 mm posterior to a line drawn through the anterior base of the
eyes (used as external reference). A volume of 3 μL of Aβ1–40, Aβ40–1
or PBS solution was injected into the lateral ventricle, at the following
coordinates frombregma:anteroposterior (AP)=−0.1 mm,mediolateral
(ML)=1mm, and dorsoventral (DV)=−2.4 mm.
Probucol was dissolved in saline (NaCl 0.9%) containing 10% of di-
methyl sulfoxide (DMSO). To investigate the effect of long-term ad-
ministration of Probucol on the cognitive and synaptic impairment,
animals received 10 mg/kg of Probucol intraperitoneally (2 mL/kg;
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weeks (ﬁrst administration 1 h after Aβ1–40, Aβ40–1 or PBS injections).
Groups treated with vehicle (NaCl 0.9% with 10% DMSO, i.p.) were
used as control.
Behavioral analysis
Twenty four hours after the last Probucol administration, dis-
placed and new object recognition tasks were conducted for evalua-
tion of learning-memory ability. The apparatus, objects and
procedures were based on a previously standardized protocol
(Thinus-Blanc et al., 1996). The apparatus was a blue plastic circular
open ﬁeld (d=44 cm; h=22 cm) with sectors drawn on the ﬂoor.
The objects were: two identical triangular rubber stoppers brown
(l=9 cm; w=6.5 cm; h=12 cm); and the object that was used to
test object novelty was a conical tube striped yellow and white
(l=9 cm; w=6.5 cm; h=12 cm). Each mouse was submitted to four
consecutive sessions (6 min in duration; 3 min intersession interval).
The ﬁrst session was used to assess locomotor activity (no objects
present) and total number of crossings and rearings were recorded.
During sessions 2, 3 and 4, two objects were presented in the open
ﬁeld with visual clues, composed by a black and white vertical striped
panel attached to the wall. In session 2, the mice were placed in the
center of the apparatus with two identical objects. Later, in the ses-
sion 3, one object wasmoved to a new location and the time spent ex-
ploring the displaced object (new location) and the non-displaced
object (old location) was recorded. In order to analyze the cognitive
performance, a location index was calculated using (Tdisplaced) /
(Tdisplaced+Tnon-displaced), where Tdisplaced is the time spent exploring
the displaced object and Tnon-displaced is the time spent exploring the
non-displaced object, as previously described (Murai et al., 2007). In ses-
sion 4, a newobjectwas added in the apparatus (replacing one of the two
familiar objects) and the time spent exploring the new object and the fa-
miliar object (old object) was calculated using (Tnew)/(Tnew+Tfamiliar),
where Tnew is the time spent exploring the new object and Tfamiliar is the
time spent exploring the old object (Hyde and Crnic, 2002). After each
session, the experimental apparatus was cleaned only with dry paper
thus minimizing the interference of potential unfamiliar smells. Five/
four animals of each group were used for biochemical analysis, while
3–4 animals were intracardiacly perfused with saline and 4% of the ﬁxa-
tive paraformaldehyde solution in 0.1 M phosphate buffer (pH 7.4) for
immunohistochemistry analysis.
Tissue preparation for biochemical analyses
Twenty four hours after of the behavioral analyses, animals (4–5
per group) were submitted to anesthesia, as described above, and
the blood was collected by cardiac puncture in heparinized tubes.
Then, the animals were killed by decapitation and hippocampus was
removed and homogenized (1:10 w/v) in HEPES buffer (20 mM, pH
7.0). The tissue homogenates were centrifuged at 3000×g, at 4 °C
for 5 min and an aliquot of the low-speed supernatant was used for
the determination of acetylcholinesterase (AChE) activity. Thereafter,
the supernatants of the ﬁrst centrifugation were further centrifuged
at 16,000×g, at 4 °C for 20 min and the supernatants obtained were
used for the determination of enzymatic activities and for the quanti-
ﬁcation of the levels of glutathione (GSH) and thiobarbituric acid re-
active substances (TBARS). Whole blood was centrifuged at 3000×g,
at room temperature for 10 min and the obtained plasma was used
to measure total cholesterol levels.
Biochemical analyses
Acetylcholinesterase (AChE) activity
Hippocampal AChE activity was measured as previously described
(Ellman et al., 1961), using acetylthiocholine iodide as a substrate.The rate of hydrolysis of acetylthiocholine iodide was measured at
412 nm through the release of the thiol compound (thiocholine),
which produces the color-forming compound TNB after reaction
with DTNB.
Antioxidant enzymes
Hippocampal glutathione reductase (GR) activity was measured
using an NADPH reduction assay following the protocol developed
by Carlberg and Mannervik (1985) using glutathione disulﬁde
(GSSG) as substrate. GR activity was monitored by decreases in
NADPH absorbance at 340 nm at 37 °C in a TECAN Genios Microplate
Reader (Tecan Group Ltd., Männedorf, Switzerland). Results were
based on a molar extinction coefﬁcient for NADPH of
6.22×103 M−1 cm−1. Hippocampal glutathione peroxidase (GPx)
activity was measured using an NADPH reduction assay following
the technique of Wendel (1981). Tissue supernatant (around 200 μg
protein) was added to a reaction mixture containing reduced gluta-
thione, glutathione reductase, and NADPH in phosphate buffer (pH
7.4). The reaction was initiated by adding tert-butyl hydroperoxide,
the absorbance decrease at 340 nm was recorded at 37 °C in a
TECAN Genios Microplate Reader (Tecan Group Ltd., Männedorf,
Switzerland). The activity in the absence of the samples was sub-
tracted. Results were based on a molar extinction coefﬁcient for
NADPH of 6.22×103 M−1 cm−1.
Cholesterol levels
Total cholesterol levels were determined in plasma by an enzy-
matic method based on the oxidase/peroxidase system using com-
mercial kit reagents (Labtest Diagnostica®, Lagoa Santa-MG, Brazil).
Glutathione levels
Hippocampal glutathione (GSH) levels were measured as non-
protein thiols based on the protocol developed by Ellman (1959).
Hippocampal homogenates were precipitated in cooled trichloroace-
tic acid 10% and centrifuged at 5000×g for 10 min, and the superna-
tant was incubated with DTNB in a 1 M phosphate buffer, pH 7.0.
Absorbance was measured at 412 nm. A standard curve of reduced
glutathione was used to calculate GSH levels.
Determination of thiobarbituric acid reactive substances levels
Thiobarbituric acid reactive substances (TBARS) were determined
in the hippocampal homogenates using the method described by
Ohkawa et al. (1979), in which malondialdehyde (MDA), an end-
product of lipid peroxidation, reacts with thiobarbituric acid to form
a colored complex. The samples were incubated at 100 °C for
60 min in acid medium containing 0.45% sodium dodecyl sulfate
and 0.67% thiobarbituric acid. After centrifugation, the reaction product
was determined at 532 nm using MDA as standard.
Protein determination
The protein content was quantiﬁed by the method of Bradford
(1976), using bovine serum albumin as a standard.
Immunohistochemistry for synaptophysin
Immunohistochemical procedures were carried out on parafﬁn-
embedded brain tissue sections using monoclonal mouse anti-
synaptophysin (1:400; Novocastra, Newcastle, UK), as previously
described (Figueiredo et al., 2011). Brieﬂy, following quenching of endog-
enous peroxidase with 1.5% hydrogen peroxide in methanol (v/v) for
20 min, high temperature antigen retrieval was performed by immersion
of the slides in awater bath at 95–98 °C in 10 mM trisodium citrate buffer
pH 6.0, for 45 min. Then, the slides were processed using the appropriate
biotinylated secondary antibody, and the streptavidin-HRP complex
(Vector Laboratories, Burlingame, CA), and according to the manufac-
turer's instructions. Subsequently, the sections were developed with
DAB (3,3′-diaminobenzidine) (Dako Cytomation, Carpinteria, CA) in
Fig. 1. Probucol (PB) reduces plasma cholesterol levels in mice. The animals were sub-
mitted to i.c.v. administration of Aβ1–40, Aβ40–1 or PBS and treated intraperitoneally
with Probucol (10 mg/kg) or vehicle, once a day, during 15 consecutive days. Plasma
cholesterol levels are expressed as mg/dL and presented as mean±S.E.M. (n=7–9
mice/group). All the ﬁve groups (including the negative control; reverse peptide)
were compared for signiﬁcant differences by analysis of variance (ANOVA). *pb0.05
when compared with the control group by one-way ANOVA followed by Tukey's mul-
tiple comparison test.
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sue sampleswere equally and simultaneously processedduring all immu-
nohistochemistry assays, and, importantly, remained under chromogen
exposition for the same period of time.
Image analysis
The immunostaining was assessed at the dorsal hippocampus, in
3-μm sections obtained between 1.6 and 2.4 mm posterior to the
Bregma. Images of stained hippocampal CA1, CA2, CA3 and dentate
gyrus (DG) were acquired using a Sight DS-5M-L1 digital camera
(Nikon, Melville, NY, USA) connected to an Eclipse 50i light micro-
scope (Nikon) at 400× magniﬁcation. Four images of each hippocam-
pal section were captured according to previously described
(Medeiros et al., 2007). The windows (ROI) for synaptophysin quan-
tiﬁcation were positioned in the CA1 and CA2 stratum radiatum,
CA3 stratum lucidum, and DG polymorph layer subregions. A thresh-
old optical density that best discriminated staining from the back-
ground was obtained using the NIH ImageJ 1.36b imaging software
(NIH, Bethesda, MD, USA), and total pixels intensity was determined
and data were expressed as optical density (O.D.). The data represent
the average value obtained by the analysis of images of the hippo-
campal CA1, CA2, CA3 and dentate gyrus.
Statistical analysis
Data were analyzed using GraphPad Prism version 5.00 for Win-
dows (GraphPad Software, San Diego, CA). Differences among the
ﬁve groups (including the negative control; reverse peptide) were
analyzed by one-way ANOVA followed by the Tukey post hoc test. Al-
ternatively, Aβ1–40 vs. Probucol interactions (excluding the negative
control; reverse peptide) were analyzed by two-way ANOVA fol-
lowed by the Bonferroni post hoc test. Results are expressed as
mean±SEM. The differences were considered signiﬁcant when
pb0.05.
Results
Probucol treatment decreases plasma cholesterol levels and did not affect
general health in mice
No signiﬁcant differences among groups were observed in general
health parameters, such as body weight, food and liquid consumption
(data not shown). Total cholesterol levels signiﬁcantly decreased in
the plasma of animals treated with Probucol (conﬁrming its hypocho-
lesterolemic effects), independently from Aβ1–40 administration
[F4,32=17.68, pb0.001] (Fig. 1). The i.c.v. Aβ1–40 treatment did not
change total cholesterol levels in plasma (Fig. 1).
Probucol treatment improves the cognitive impairment induced by Aβ1–40
In order to evaluate the effects of i.c.v. Aβ1–40 injection on mouse
cognitive performance, a two-trial object recognition task was used
(see Material and methods section). Aβ1–40 administration caused a
signiﬁcant decline in the spatial memory [F4,32=4.25; pb0.01], as in-
dicated by a decrease in the time spent in the displaced object during
the 3rd test session when compared to controls (Fig. 2C). Moreover,
Aβ1–40 administration caused in a signiﬁcant decline in the capacity
of recognizing a previous presented experience [F4,32=3.723;
pb0.05], as indicated by a decrease in the time exploring the new ob-
ject during the 4th test session when compared to controls (Fig. 2D).
Probucol treatment prevented the Aβ1–40-induced cognitive deﬁcits
in both tests sessions (Figs. 2C and D) and no cognitive deﬁcits were
observed in mice treated with the inverse peptide (Aβ40–1; negative
control). No signiﬁcant differences in the number of crossed squares
and rearing behavior were observed among the experimental groups
(Figs. 1A and B), indicating that the changes observed in the objectrecognition tasks were not related to motor impairment (Figs. 2A
and B).
Probucol treatment improves the synaptic deﬁcits induced by Aβ1–40
To further explore potential events involved in the Aβ1–40-induced
cognitive deﬁcits, we assessed the levels of the presynaptic protein
synaptophysin in the hippocampus 15 days after the beginning of
treatments (24 h after the behavioral sessions). The Aβ1–40 treatment
resulted in a signiﬁcant loss of synaptic marker synaptophysin in the
mouse hippocampus and Probucol treatment signiﬁcantly attenuated
this effect [F4,11=4.976, pb0.05] (Fig. 3). These data suggest that Pro-
bucol might protect against the Aβ1–40-induced cognitive failure
through a reduction of the synaptic changes induced by the peptide.
Probucol treatment prevents the increase in acetylcholinesterase (AChE)
activity induced by Aβ1–40
Aβ1–40 injection signiﬁcantly increased hippocampal AChE activity
15 days after the peptide administration [F4,18=4551; Pb0.05] and
Probucol, which did not affect AChE activity per se, blunted the stimula-
tory effect played by Aβ1–40. The inverse peptide (Aβ40–1; negative con-
trol) did not change hippocampal AChE activity (Fig. 4).
Probucol treatment modulates the hippocampal glutathione reductase
activity
The antioxidant glutathione (GSH) system is an important tool
mediating protection against several (pro)-oxidant molecules in the
CNS (Dringen and Hirrlinger, 2003) and the dyshomeostasis of this
system is involved in several neuropathological conditions (Lee et
al., 2010; Lovell et al., 1998). Probucol treatment caused a signiﬁcant
increase in hippocampal glutathione reductase (GR) activity as indi-
cated by a signiﬁcant main effect in a two-way ANOVA (Aβ1–40 and
Probucol as independent variables) [F1,15=6.059, Pb0.05] (Fig. 5A).
Moreover, one-way ANOVA showed a signiﬁcant increase in hippo-
campal GR activity in animals treatment with Probucol (i.p.) and in
animals treatment with Probucol (i.p) plus Aβ1–40 (i.c.v.)
[F4,18=4.551, Pb0.05] (Fig. 5A). Hippocampal GSH content and gluta-
thione peroxidase (GPx) activity were not signiﬁcantly different
among groups (data not shown).
Hippocampal lipid peroxidation increased in Aβ1–40-treated ani-
mals [F4,18=2.525, P=0.07] and Probucol treatment blunted this
event (Fig. 5B). It is noteworthy that animals treated with the inverse
peptide (Aβ40–1) showed a similar hippocampal lipid peroxidation to
Fig. 2. Probucol (PB) attenuates cognitive impairment induced byAβ1–40 inmice. The animalswere submitted to i.c.v. administration of Aβ1–40, Aβ40–1 or PBS and treated intraperitoneally
with Probucol (10 mg/kg) or vehicle, once a day, during 15 consecutive days. Locomotor (A) and exploratory (B) activities, aswell as the recognition of displaced (C) and new (D) objects,
were evaluated at 24 h after the last Probucol administration. The results are expressed as the total number of crossings (A), total number of rearings (B), the ratio between times spent in
the displaced (C) or new (D) objects and the total time spent in both objects (displaced+nondisplaced or new+familiar). Data are presented asmean±S.E.M. (n=7–9mice/group). All
the ﬁve groups (including the negative control; reverse peptide) were compared for signiﬁcant differences by analysis of variance (ANOVA). *pb0.05 when compared with the control
group by one-way ANOVA followed by Tukey's multiple comparison test.
771D.B. Santos et al. / Experimental Neurology 233 (2012) 767–775that of control animals (Fig. 5B). A signiﬁcant positive correlation was
found for hippocampal TBARS levels and AChE activity [r=0.66,
Pb0.01].
Discussion
The present results show that a two-week treatment of adult mice
with Probucol, a phenolic lipid-lowering agent with anti-
inﬂammatory and antioxidant properties, protected against behavioral
and hippocampal biochemical changes induced by a single i.c.v. admin-
istration of Aβ1–40, signiﬁcantly attenuating Aβ1–40-induced impair-
ments in the object recognition memory and hippocampal lipid
peroxidation, synaptic dyshomeostasis and changes in acetylcholines-
terase activity. To the best of our knowledge, this is the ﬁrst in vivo
study reporting the beneﬁcial effects of this “non-statin” cholesterol-
lowering drug in an experimental model of AD based on Aβ-mediated
neurotoxicity.
Loss of memory and impairment of cognitive functions represent
classical signs observed in AD patients (Mattson, 2004a,b), which
have been directly correlated with Aβ deposition (Cummings et al.,
1996). Our experimental protocol (based on the i.c.v. infusion of
Aβ1–40 in mice) caused a signiﬁcant decline in the object recognition
memory, which is highly dependent upon the hippocampal system
(Broadbent et al., 2010). Importantly, the i.c.v. infusion of Aβ40–1 (re-
verse peptide) did not affected the ability of animals in recognizing
both the new and replaced objects, indicating that the observed be-
havioral impairments in Aβ1–40-exposed animals were dependent
on the peptide sequence/structure, supporting the relevance of the
chosen experimental model (Figueiredo et al., 2011; Medeiros et al.,
2007; Piermartiri et al., 2010). It is noteworthy that this protocol
also caused signiﬁcant cognitive impairments in mice whenevaluated in others cognitive tasks (i.e., Moris water maze test;
Medeiros et al., 2007; Prediger et al., 2007), reinforcing the impor-
tance of a potential relationship between cognitive behavior and synap-
tic function in our experimental model.
Synapse loss at speciﬁc encephalic structures of AD patients signiﬁ-
cantly correlates with the severity of their cognitive symptoms (Scheff
et al., 2006). In our experimental model, i.c.v. Aβ1–40 infusion signiﬁ-
cantly decreased the hippocampal levels of synaptophysin, the major
synaptic vesicle protein (consequently, a speciﬁc pre-synaptic marker),
although no effects were observed in animals exposed to the reverse
peptide (Aβ40–1). The decreased synaptophysin levels and the impaired
object recognition memory in Aβ1–40-exposed mice greatly suggest a
link between both events; the synaptotoxic effects of Aβ1–40 might be
crucial in causing the observed memory deﬁcits. This idea is reinforced
by the fact that Probucol, which prevented Aβ1–40-induced synaptic
changes, also blunted the deleterious effects of Aβ1–40 on the recogni-
tion object memory.
The actual mechanisms related to the beneﬁcial effects of Probucol
against Aβ1–40-induced synaptic and cognitive impairments cannot
be completely explained only based on the presented results. In
fact, experimental and clinical studies have shown that Probucol de-
creases the progression of atherosclerosis (Regnstrom et al., 1996),
protects vasculature (Poirier, 2003), acts as an antioxidant molecule
(Singla et al., 2007), enhances neurogenesis (Champagne et al.,
2003), inhibits thrombosis (Tanous et al., 2006), modulates the activity
of antioxidant enzymes (Farina et al., 2009) and possesses anti-
inﬂammatory properties (Pfuetze and Dujovne, 2000). Taking into ac-
count the numerous factors involved in the toxicity elicited by Aβ (i.e.,
inﬂammation, oxidative stress, glutamate and calcium dyshomeostasis,
modulation of cholesterol homeostasis — (Longenberger and Shah,
2011; Tabner et al., 2006), all the aforementioned Probucol properties
Fig. 3. Probucol (PB) prevents Aβ1–40-induced synaptic disruption in mice. The animals were submitted to i.c.v. administration of Aβ1–40, Aβ40–1 or PBS and treated intraperitoneally
with Probucol (10 mg/kg) or vehicle, once a day, during 15 consecutive days. (A) Representative images of synaptophysin immunoreactivity in CA1, CA2, CA3 and dentate gyrus
(DG) subregions of mice hippocampus (scale bar=50 μm). (B) Relative quantiﬁcation of synaptophysin optical density in hippocampal subregions CA1, CA2, CA3, and DG. Values
represent the mean±S.E.M. (n=3–5 mice/group). All the ﬁve groups (including the negative control; reverse peptide) were compared for signiﬁcant differences by analysis of
variance (ANOVA). *pb0.05 when compared with the control group by one-way ANOVA followed by Tukey's multiple comparison test.
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model. Of particular importance, neuroinﬂammatory-like changes
have been found in the hippocampus of rodent with memory impair-
ment caused by Aβ administration (Medeiros et al., 2007). Because Pro-
bucol is an anti-inﬂammatory drug, the control of neuroinﬂammation
might be a possiblemechanism bywhich Probucol affords neuroprotec-
tion in our experimental protocol. In addition, it is important to note
that the i.c.v. Aβ1–40 infusion increased the levels of hippocampal lipid
peroxidation and Probucol signiﬁcantly blunted this phenomenon.
These results suggest that oxidative stress played an important role in
mediating the deleterious effects of Aβ1–40 toward hippocampal synap-
ses and that the antioxidant properties of Probucol were important in
counteracting Aβ1–40 effects. This idea is supported by studies reporting
the pro-oxidative properties of Aβ1–40 (Medeiros et al., 2007;
Piermartiri et al., 2010; Tabner et al., 2006), as well as the antioxidant
properties of Probucol (Farina et al., 2009; Park et al., 2007). Although
Probucol treatment was able to increase hippocampal glutathione re-
ductase (GR) activity, which could contribute to the observed beneﬁcialeffects against Aβ1–40-mediated synaptic impairment, its direct scav-
enging abilities (Bridges et al., 1991) might also explain its positive ef-
fects in decreasing Aβ1–40-induced hippocampal lipid peroxidation
and, consequently, synaptotoxicity.
Although it is likely that Probucol's antioxidant properties contribute
to its beneﬁcial effects against Aβ1–40-induced synaptic and cognitive
impairments, such beneﬁt could also be related to itsmodulatory effects
toward cholesterol metabolism. Of particular importance, recent ﬁnd-
ings lend support to the notion that progressive deterioration of choles-
terol homeostasis in AD is a central player in the disease
pathophysiology (for a review, see Leduc et al., 2010). Cholesterol has
been linked to the amyloidogenesis process (Guardia-Laguarta et al.,
2009) and was shown to accumulate in senile plaques of AD patients
and in transgenic mice (Mori et al., 2001). On the other hand, hypocho-
lesterolemic agents have presented beneﬁcial effects in experimental
models of AD, as well as in clinical/epidemiological studies (Haag et al.,
2009; Piermartiri et al., 2010). Of particular importance, statins, which
represent widely used drugs that reduce cholesterol synthesis by
Fig. 4. Probucol (PB) prevents the increase of AChE activity induced by Aβ1–40 in the
hippocampus of mice. The animals were submitted to i.c.v. administration of Aβ1–40,
Aβ40–1 or PBS and treated intraperitoneally with Probucol (10 mg/kg) or vehicle,
once a day, during 15 consecutive days. Enzyme activity is expressed as nmol of sub-
strate hydrolyzed/min/mg protein and presented as mean±S.E.M. (n=4–5 mice/
group). All the ﬁve groups (including the negative control; reverse peptide) were com-
pared for signiﬁcant differences by analysis of variance (ANOVA). *pb0.05 when com-
pared with the control group by one-way ANOVA followed by Tukey's multiple
comparison test.
Fig. 5. Probucol (PB) prevents the decrease in glutathione reductase (GR) activity in-
duced by Aβ1–40 in the hippocampus of mice. The animals were submitted to i.c.v. ad-
ministration of Aβ1–40, Aβ40–1 or PBS and treated intraperitoneally with Probucol
(10 mg/kg) or vehicle, once a day, during 15 consecutive days. Hippocampal glutathi-
one reductase (GR) activity (A) is expressed as nmol of NADPH oxidized/min/mg pro-
tein and thiobarbituric acid reactive substances (TBARS) levels (B) are expressed as
nmol of MDA/mg protein. Data are presented as mean±S.E.M. (n=4–5 mice/group).
All the ﬁve groups (including the negative control; reverse peptide) were compared
for signiﬁcant differences by analysis of variance (ANOVA). *pb0.05 when compared
with the control group by one-way ANOVA followed by Tukey's multiple comparison
test. #p=0.07 when compared with the control group by one-way analysis of variance
(ANOVA) followed by Tukey's multiple comparison test.
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tase (Jick et al., 2000; Rockwood et al., 2002), have been reported to re-
duce risk and progression of AD (Haag et al., 2009). A recent study
showed that atorvastatin prevented hippocampal damage induced by
aggregated Aβ1–40 infusion (exposure schedule identical to ours)
(Piermartiri et al., 2010), suggesting that statins not only prevent Aβ ag-
gregation (as reported by Longenberger and Shah, 2011), but also play
protective effects by decreasing the toxicity induced by aggregated Aβ.
Interestingly, Probucol also protected against the toxic effects elicited
by i.c.v. infused Aβ1–40, suggesting that both hypocholesterolemic
agents could act similarly in protecting against Aβ1–40-toxicity. Howev-
er, an additional advantage of Probucol when compared to statins could
be its high antioxidant activity, which seems to protect against Aβ1–40-
induced oxidative damage. Moreover, experimental evidences indicate
that Probucol increased the hippocampal levels of apoE and its main re-
ceptor (LRP) (Champagne et al., 2003), which is crucial in mediating
brain-to-blood Aβ clearance (Zlokovic et al., 2010). Thus, one could sup-
pose that, in addition to its antioxidant effects, Probucol might protect
against Aβ1–40-induced synaptic and cognitive impairments by modu-
lating cholesterolmetabolism, aswell as apoE and LPR expression. How-
ever, additional studies are necessary to prove this hypothesis. The
levels of plasma cholesterol were decreased in Probucol treated animals.
Preliminary studies from our laboratory (not published) have shown
that brain cholesterol levels are not signiﬁcantly changed after Probucol
treatment in mice. However, we do not know about the distribution of
brain cholesterol into speciﬁc hippocampalmembrane regions (particu-
larly, lipid rafts) after Probucol treatment. This constitutes a very inter-
esting ﬁeld that deserves additional research.
Because dose–response in vivo studies concerning the hypocholester-
olemic effects of Probucol inmice are lacking in the literature, we have no
comparative basis to afﬁrm whether the Probucol's dosage (10 mg/kg;
during 2 weeks) used in our study represented a supra-maximal effective
dose. Nevertheless, it was noteworthy that the chosen dosage (based on
Siveski-Iliskovic et al., 1995)decreased around45%of plasma total choles-
terol levels, indicating a highly effective pharmacological effect. Although
it is difﬁcult to extrapolate our protocol to human conditions, similar
doses have been used in clinical trials (Jeon et al., 2011; Kasai et al.,
2011; Reaven et al., 1992), where the daily dose of 1 g and 500 mg for
patients would be equivalent to approximately 14 mg/kg/day and
7 mg/kg/day, respectively, considering a mean body weight of 70 kg
for an adult human. Interestingly, experimental studies with rabbits
and rodents showed that a similar dose of Probucol (approximately
10 mg/kg) leaded to plasmatic Probucol concentrations ranging from
43 to 58 μg/mL, which are comparable to those found in the plasma of
humans receiving a standard oral dose of 1 g of Probucol per day
(Aburatani et al., 1988; Kita et al., 1988; Shankar et al., 1989).
The close relationship between the cholinergic system and the
pathogenesis and symptoms of AD is a well reported phenomenon
(Van Beek and Claassen, 2011). Of particular importance, a severe
loss of cholinergic innervations has extensively been documented
during the advanced stages of late-onset AD (Schliebs and Arendt,
2011). Acetylcholinesterase (AChE) inhibitors provide beneﬁcial ef-
fects in AD patients (ameliorating cognitive skills), at least in the be-
ginning of the progressive disease (Holzgrabe et al., 2007).
Paradoxically, despite the overall loss of AChE in the brain of AD pa-
tients (Atack et al., 1983), AChE activity is increased in plaques and
tangles very early in the process of amyloid deposition (Moran et
al., 1993; Ulrich et al., 1990). Moreover, a recent study showed that
AD patients presented a higher plasma AChE activity when compared
to subjects of the same age (Garcia-Ayllon et al., 2010). Such event
was correlated with an increase in the G(1)+G(2) forms, the subset
of AChE species which are increased in brain of AD patients (Garcia-
Ayllon et al., 2010). The mechanism by which AChE expression is
upregulated around amyloid plaques is unclear, but appears to be
due to a disturbance in calcium homeostasis (Sberna et al., 1997).
Our results showed that i.c.v. Aβ1–40 infusion increased hippocampal
774 D.B. Santos et al. / Experimental Neurology 233 (2012) 767–775AChE activity. In addition, Probucol treatment, which did not change
AChE activity per se, blunted the stimulatory effect of Aβ1–40 toward
hippocampal AChE. Based on the potential involvement of calcium
dyshomeostasis in the increased AChE activity near to amyloid pla-
ques (Sberna et al., 1997) and the close relationship between calcium
dyshomeostasis and oxidative stress (Lafon-Cazal et al., 1993), one
could suppose a potential relationship between oxidative stress and
increased AChE activity in the hippocampus of Aβ1–40-exposed
mice. Accordingly, experimental evidences have reported increased
AChE activity in the CNS during oxidative stress events (Khadrawy
et al., 2011). Probucol, whose beneﬁcial effects against Aβ1–40-in-
duced synaptic and memory impairments seems to be related to its
antioxidant properties, also decreased hippocampal AChE activity in
Aβ1–40-exposed mice. In this regard, it was noteworthy the observed
signiﬁcant positive correlation between hippocampal lipid peroxida-
tion and AChE activity, reinforcing the potential relationship between
oxidative stress and increased AChE activity (both events abolished
by Probucol treatment).
In conclusion, the present ﬁndings reinforce and extend the notion
of the hazardous effects of Aβ1–40 toward hippocampal synaptic ho-
meostasis and cognitive performance. In addition, they indicate that
Probucol is able to counteract the behavioral and biochemical impair-
ments induced by i.c.v. Aβ1–40 administration in mice. The antioxi-
dant properties of Probucol are likely related to its beneﬁcial effects,
although the involvement of cholesterol metabolism modulation in
this beneﬁt cannot be ruled out. The study is the ﬁrst to report the
protective effects of Probucol (a “non-statin cholesterol-lowering
drug”) against Aβ1–40-induced synaptic and behavioral impairments,
rendering this compound a promising molecule for further pharma-
cological studies on the search for therapeutic strategies to treat or
prevent AD.
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